Fig.2 | Scientific Reports

Fig.2

From: PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab

Fig.2

Representative images of the tumor before and during pembrolizumab monotherapy in a patient with pancreatic metastasis of salivary duct carcinoma. (a) Pre-treatment of the patient with pancreatic metastasis. (b) Tumor shrinkage observed 63 days after the initiation of pembrolizumab monotherapy. (c) Tumor disappeared 154 days after the initiation of pembrolizumab monotherapy.

Back to article page